Robenacoxib

Indications

Robenacoxib tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration, in cats ≥ 5.5 lbs (2.5 kg) and ≥ 4 months of age; for up to a maximum of 3 days.

Dosage and Administration

Always provide "Information for Cat Owners" Sheet with prescription. Carefully consider the potential benefits and risks of Robenacoxib tablets and other treatment options before deciding to use Robenacoxib tablets. Use the lowest effective dose for the shortest duration consistent with individual response. The dose of Robenacoxib tablets is 0.45 mg/lb (1 mg/kg) orally once daily, for a maximum of 3 days. See dosing chart for dosage directions. Dosage Directions: For oral use in cats ≥ 5.5 lbs and ≥ 4 months of age; for up to a maximum of 3 days. Tablets are not scored and should not be broken. Body weight 6 mg Robenacoxib Tablets 5.5 to 13.2 lbs (2.5 to 6 kg) 1 whole tablet once daily 13.3 to 26.4 lbs (6.1 to 12 kg) 2 whole tablets once daily Do not use in cats weighing less than 5.5 lbs, as cats less than 5.5 lbs cannot be accurately dosed. The first dose should be administered approximately 30 minutes prior to surgery, at the same time as the pre-anesthetic agents are given. Robenacoxib tablets may be given with or without food. In cats ≥ 5.5 lbs and ≥ 4 months of age, subsequent doses can be given via the oral tablet, or interchanged with subcutaneous injection for a maximum of 3 total robenacoxib doses over 3 days, not to exceed one dose per day (see Animal Safety and the robenacoxib injection package insert). Note the dose of Robenacoxib tablets and robenacoxib injection are different. If a second and third tablet dose is dispensed to the client to administer at home, doses should be dispensed in the dispensing envelope with the attached Information for Owner Sheet intact. Do not remove Information for Cat Owner Sheet. Record when the first dose was administered on the dispensing envelope. Cats weighing ≥ 13.3 lbs may require two blister cards, each dispensed in an individual dispensing envelope.

Contraindications

Robenacoxib tablets should not be used in cats that have a hypersensitivity to robenacoxib or known intolerance to NSAIDs.

Warnings

Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For oral use in cats only. All cats should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory tests should be conducted to establish hematological and serum biochemical baseline data prior to administration of an NSAID. Owners should be advised to observe for signs of potential drug toxicity (see Adverse Reactions and Animal Safety) and be given an "Information for Cat Owners" Sheet about Robenacoxib tablets. Do not administer robenacoxib tablets or injection in conjunction with any other oral or injectable NSAID or corticosteroid. Keep Robenacoxib tablets in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

Precautions

When using NSAIDS such as Robenacoxib, the use of fluid therapy during surgery is recommended to decrease potential renal complications (see Adverse Reactions, Post-Approval Experience ). Appetite should be monitored in cats receiving Robenacoxib. Stop administration of Robenacoxib if appetite decreases or if the cat becomes lethargic. The use of Robenacoxib tablets has not been evaluated in cats younger than 4 months of age and weighing less than 5.5 lbs, cats used for breeding, or in pregnant or lactating cats. Cats receiving Robenacoxib should weigh at least 5.5 lbs. The use of Robenacoxib in cats with cardiac disease has not been studied. Robenacoxib has been shown to prolong the QT interval. As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal, and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Cats that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for adverse events are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Anesthetic drugs may affect renal perfusion; approach concomitant use of anesthetics and NSAIDs cautiously. Appropriate monitoring procedures (including ECG, blood pressure, and temperature regulation) should be employed during all surgical procedures. The use of parenteral fluids during surgery is recommended to decrease potential renal complications when using NSAIDs perioperatively. If additional pain medication is needed after a daily dose of Robenacoxib, a non-NSAID/non-corticosteroid class of analgesic may be necessary. Concurrent administration of potentially nephrotoxic drugs should be carefully approached and monitored. NSAIDs may inhibit prostaglandins which maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. NSAIDs possess the potential to produce gastrointestinal ulcerations and/ or gastrointestinal perforations. Do not use Robenacoxib concomitantly with other anti-inflammatory drugs, such as NSAIDs or corticosteroids. Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use. Robenacoxib tablets and robenacoxib injection are safe to use interchangeably when given once a day for a maximum of 3 days in cats ≥ 4 months of age and ≥ 5.5 lbs. Note the dose of Robenacoxib tablets and robenacoxib injection are different. The use of concomitantly protein-bound drugs with robenacoxib has not been studied in cats. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of robenacoxib has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy. Concurrent medications used during the field study with robenacoxib tablets included antiparasiticides, anesthetics, pre-anesthetic medications, and antibiotics. The effect of cyclo-oxygenase inhibition and the potential for thromboembolic occurrence or a hypercoagulable state has not been evaluated. It is unknown whether cats with a history of hypersensitivity to ß lactam drugs will exhibit hypersensitivity to Robenacoxib. Robenacoxib is poorly soluble in water and in acid solutions readily degrades to form γ-lactam. In cats, lactam is a metabolite of robenacoxib. Additionally, lactam is a degradation product that increases over the shelf-life of the tablets. Neurologic signs have been associated with the use of ß lactam drugs; it is unknown if the lactam in robenacoxib may cause similar neurologic signs (see Animal Safety ). Occurrences of seizures, ataxia, and nystagmus have been associated with the use of robenacoxib. Robenacoxib may prolong the QT interval; the associated risk of developing ventricular arrhythmia is unknown. The use of robenacoxib with other drugs shown to prolong the QT interval is not recommended. Commonly used drugs that prolong the QT interval include antihistamines, prokinetic drugs, and certain anesthetic drugs. As a class, it is unknown if the use of NSAIDs in asthmatic cats can cause acute exacerbations, as seen in some humans.

Adverse Reactions

In a controlled field study, a total of 249 male and female cats representing 6 breeds, 6 months to 13 years old, weighing 5.5 – 15 lbs were included in the field safety analysis. The following table shows the number of cats exhibiting each observation. Adverse Reactions in the Postoperative Pain Field Study 1 Adverse Reaction Robenacoxib 6 mg Tablets for Cats (robenacoxib) n = 167 Placebo (vehicle control) n = 82 Incision site bleeding 7 1 Incision site infection 6 2 Inappetance, weight loss 4 2 Decreased activity, lethargy 4 1 Vomiting 4 1 Cystitis, hematuria 3 0 Hematachezia, diarrhea 3 1 Hair loss, excoriation, bruising 2 0 Respiratory, cardiac arrest 1 0 Incoordination, weakness 1 1 Death 0 1 1 Cats may have experienced more than one of these signs during the study. The most commonly reported adverse reactions were surgical site bleeding, infected surgery sites, lethargy, vomiting and inappetance. Changes in the clinical pathology values were not considered clinically significant. Post Approval Experience (2015) The following adverse events are based on voluntary, post approval reporting. Not all adverse events are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data. The signs reported are listed in decreasing order of reporting frequency: Anorexia, depression/ lethargy, vomiting, elevated BUN, elevated creatinine, renal insufficiency/ failure, diarrhea, weight loss, dehydration. In some cases, death has been reported. Some of these cases involved patients that developed renal failure/renal insufficiency.

Description

Robenacoxib is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID) of the coxib class. Tablets are round, off white to beige colored, speckled, not scored, flavored and contain 6 mg robenacoxib. The molecular weight of robenacoxib is 327.28. The empirical formula is C16-H13-F4-NO2. Robenacoxib is [5-Ethyl-2-(2,3,5,6-tetrafluoro-phenylamino)-phenyl]-acetic acid. The structural formula is: Image

Information for Owners

Robenacoxib, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include vomiting, diarrhea, decreased appetite, dark or tarry stools, increased water consumption, increased urination, anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes. Serious adverse reactions associated with this drug class can occur without warning and may result in death (see Warnings and Adverse Reactions). Owners should be advised to discontinue Robenacoxib tablets and contact their veterinarian immediately if signs of intolerance are observed. The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate, is initiated.

Storage

Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (59° - 86°F). Manufactured by: Zydus Animal Health and Investments Limited, Ahmedabad, India Distributed by: ZyVet Animal Health Inc. Pennington, NJ 08534

Other labels for this ingredient

These labels are also stored for the same active ingredient. They are not identical to the one reprinted above, and each is listed by product and set id rather than merged with it.

• Robenacoxib 6 mg Tablets for Cats, Covetrus North America. Set id d7ebad2b-2e8f-458b-88fb-6a08e2ffd1fd.
• OstiRobe TM (robenacoxib) 6 mg Tablets for Cats, MWI ( VetOne). Set id b16da650-5be9-4f2b-bfa8-07cd754a171a.
• onsior™ (robenacoxib) 6 mg Tablets for Cats, Elanco US Inc.. Set id 922d3235-085e-454f-9535-44ef4bca12f4.
• Robenacoxib Injection, Cronus Pharma LLC. Set id b50502d4-e4b1-4fd2-818f-9aa86bad71a4.
• VETOne OstiRobe TM Injection (robenacoxib), MWI Animal Health. Set id a19ab82f-4ff9-4951-a3cc-decfa79e6e5d.
• onsior™ (robenacoxib), Elanco US Inc.. Set id f4f307a0-88b5-4740-b198-35edef954bf1.

FDA adverse event reports

The FDA Center for Veterinary Medicine publishes the adverse event reports it receives through openFDA. The counts below are the reports naming robenacoxib as an active ingredient for each species this label names, as returned on 2026-09-16, coded by the VeDDRA reaction term the reporter chose. Reactions are counted per report, so one report can appear under several terms.

These are counts, not rates. Reporting is voluntary, the number of animals treated is not known, and a widely used product accumulates reports for that reason alone. A report records that an event followed a dose; it does not establish that the product caused it. The counts say nothing about how one product compares with another.